6 Best Peptides for Graves' Disease

What to Know Before Choosing a Peptide for Graves' Disease

Graves' disease is not a straightforward condition to approach with peptide therapy. The disease is driven by the immune system producing antibodies that continuously stimulate the thyroid gland, causing it to overproduce hormones in a way the body cannot self-regulate. That autoimmune mechanism means any peptide someone considers for this goal is working, if it is working at all, upstream of the thyroid itself, on immune regulation, gut barrier integrity, or tolerance restoration, rather than on thyroid hormone levels directly.

A peptide earns a slot on this list because people use it for Graves' disease, or are actively discussing using it for this goal. That is the whole test. FDA-approved compounds, telemedicine-prescribed compounds, and research-only compounds are all eligible, and so are compounds that appear only in community protocols and off-label clinical discussions. Evidence strength is never the filter for inclusion. It is the honest description inside each entry. That means this list includes compounds that have been through early human trials, compounds that exist only in animal research, and compounds with no controlled trial data for this specific condition at all. Each entry states its evidence plainly so the reader can weigh the options accurately.

These compounds are numbered by how prominently each appears in the published research and in documented real-world use for Graves' disease specifically. That order gives the list a logical shape, but it is not a ranking of one compound over another. Which peptide, if any, belongs in someone's protocol depends on their situation, their current treatment plan, and a direct conversation with a qualified clinician.

One important framing note before the entries: conventional medical treatment for Graves' disease, including antithyroid medications, beta-blockers, radioactive iodine, and surgery, remains the standard of care. No peptide replaces that. The compounds here are being explored as potential adjuncts or future therapeutics, and they earn discussion because the disease involves immune pathways that several of these compounds are known to influence. That context shapes how to read every entry that follows.

1. ATX-GD-59: The Only Peptide Tested in Human Graves' Trials

ATX-GD-59 is a synthetic peptide therapy developed specifically for Graves' disease, which makes it unique on this list. Every other compound here was developed for a different purpose and has been explored in a Graves' context off-label or theoretically. ATX-GD-59 was designed from the ground up to address the immune mechanism that drives the disease.

The approach is called antigen-specific immunotherapy. Graves' disease is caused, at the molecular level, by the immune system misidentifying part of the thyroid-stimulating hormone receptor (the TSHR) as a foreign threat. Two synthetic peptides in ATX-GD-59 mimic pieces of the TSHR structure. When administered, these peptides bind to HLA-DR molecules on dendritic cells, which are key immune coordinators, without triggering the activation signals that would normally follow that binding. That tolerogenic presentation encourages the immune system to generate T-regulatory cells, a class of cells whose job is to suppress inappropriate immune responses. The goal is to gradually restore immune tolerance to the TSHR, reducing the antibody production that drives uncontrolled thyroid stimulation.

The human evidence base consists of a Phase 1 open-label trial that enrolled twelve Graves' patients who had not yet started antithyroid drugs. In an open-label trial without a control group, results are preliminary rather than definitive: five of ten evaluable patients achieved normal free triiodothyronine levels, the key thyroid hormone elevated in active Graves' disease, and TSH receptor antibody concentrations decreased across the group. No Phase 2 or Phase 3 results have been published as of 2026. That makes ATX-GD-59 the compound with the most Graves'-specific human evidence on this list, while still sitting far below the evidence bar that would establish it as a treatment.

ATX-GD-59 is not commercially available. It cannot be obtained through telemedicine platforms or compounding pharmacies. Access is restricted to clinical trial enrollment only. This compound belongs on the list because it represents the clearest signal in the published research of where Graves'-specific peptide therapy is heading, even if the path to a usable clinical tool remains long.

2. P19: Preclinical TSHR-Derived Peptide with Strong Animal Data

P19 is a cyclic peptide derived from the structure of the TSHR, the same receptor that Graves' antibodies target. Like ATX-GD-59, it was developed with Graves' disease specifically in mind. Unlike ATX-GD-59, P19 has never been administered to a human being.

The mechanism differs from the immunotherapy approach. P19 is thought to function as an antibody scavenger, competing for anti-TSHR antibody binding, or to induce the production of blocking IgG4 antibodies, a type that occupies the TSHR without activating it. Rather than retraining the immune system, this approach aims to neutralize the pathogenic antibodies already in circulation or fill receptor binding sites with non-activating antibodies, reducing the unregulated stimulation that causes hyperthyroidism. Importantly, P19 does not directly block the TSH receptor, which distinguishes it from approaches that carry side effects associated with direct receptor antagonism.

The preclinical data is among the strongest for any Graves'-specific peptide in animal research. In a long-term Graves' disease mouse model, P19 significantly reduced TSHR-binding inhibitory immunoglobulins, the measure of pathogenic antibody activity, with statistical significance reaching p less than 0.0001, and reduced free T4 levels at p equal to 0.02. It also reduced orbital tissue changes, specifically mucin and collagen deposition around the eye, which matters because Graves' orbitopathy, the eye involvement associated with the disease, is a particularly difficult complication to address. These results were confirmed in an independent second laboratory, adding meaningful weight to a preclinical finding.

No human trial data has been published for P19 as of 2026. It is not available through any human-use channel. Its position on this list reflects its prominence in the published research and the fact that peer-reviewed discussion of experimental peptide approaches to Graves' disease consistently centers on it as a leading preclinical candidate.

3. Cyclic Peptide 836: A Second Preclinical Candidate from the Same Research Track

Cyclic Peptide 836 is another TSHR-derived cyclic peptide developed for Graves' disease research, sharing the same fundamental strategy as P19: mimicking structural elements of the TSHR to interfere with the pathogenic antibody cycle rather than blocking the receptor directly.

The mechanism centers on the 8th cylindrical loop of the TSHR's leucine-rich repeat domain. Like P19, the compound is hypothesized to act as an antibody scavenger or to induce non-activating blocking antibodies that occupy the TSHR without triggering thyroid stimulation. The absence of direct receptor antagonism is again considered an advantage, as it may sidestep adverse effects associated with compounds that physically block the receptor.

In animal models using six monthly injections, the results spanned the core features of Graves' disease pathology: thyroid hyperplasia, retro-orbital fibrosis, tachycardia, and cardiac hypertrophy were all markedly reduced, and T4 levels normalized by approximately week fifteen. These findings were published in the peer-reviewed journal Endocrinology. The animal safety profile was characterized as favorable, consistent with the mechanism's avoidance of direct receptor blockade.

No human clinical trial data exists for Cyclic Peptide 836 as of 2026. Like P19, it is not available for human use through any channel. It appears here because it is consistently present in the published preclinical literature on peptide approaches to Graves' disease, and that body of research is part of the landscape anyone studying this field will encounter.

4. Thymosin Alpha-1: Off-Label Immune Modulation with Autoimmune Thyroid Discussion

Thymosin Alpha-1 is a 28-amino acid thymic peptide with a documented role in immune regulation that extends across multiple conditions. It is not a Graves'-specific compound and has never been evaluated in a clinical trial for Graves' disease. Its presence in this conversation comes from the overlap between its general immune-modulating properties and the immune pathways involved in autoimmune thyroid disease.

The mechanism driving discussion here is Thymosin Alpha-1's effect on T-regulatory cells, the same Treg cells that ATX-GD-59 aims to activate through antigen-specific presentation. Thymosin Alpha-1 promotes T-cell maturation and is thought to support Treg activity broadly, without the disease-specific targeting of a Graves' therapy. The reasoning linking it to autoimmune thyroid disease runs through shared immune pathway involvement: if inappropriate immune activation drives the condition, and if Thymosin Alpha-1 modulates that activation by supporting regulatory immune function, there is a theoretical basis for relevance. There is also a published evidence base for reducing thyroid peroxidase antibodies in Hashimoto's thyroiditis, a different autoimmune thyroid condition that shares some immune pathway overlap with Graves'.

The evidence for Thymosin Alpha-1 in Graves' disease is anecdotal and theoretical. No peer-reviewed human trial has examined it for Graves'. Extrapolating the Hashimoto's antibody data to Graves' involves assumptions the research has not confirmed, and the two conditions have distinct enough mechanisms that findings from one do not reliably transfer to the other. What exists for Graves' is user-reported experience from people managing autoimmune thyroid conditions who have incorporated Thymosin Alpha-1 into broader protocols, typically alongside conventional antithyroid treatment rather than in place of it.

Thymosin Alpha-1 is not FDA-approved for any indication in the United States. It is used in some countries for other conditions, and in the Graves' context, access is through research channels or off-label via integrative practitioners using it in immune-modulating protocols. One caution specific to Graves' applies broadly to immune-active peptides: any compound influencing immune activity in an autoimmune condition carries a theoretical risk of worsening the immune dysregulation it is meant to address.

5. BPC-157: Gut Repair and an Indirect Route to Immune Relevance

BPC-157 is a synthetic peptide derived from a protein found in gastric juice and is among the most widely discussed compounds in general peptide communities. Its primary studied applications involve gut mucosal repair, tissue healing, and reduction of inflammatory signaling. The connection to Graves' disease is indirect, running through the relationship between gut barrier integrity and systemic immune activity.

The mechanism relevant to autoimmune thyroid discussions is gut barrier repair. BPC-157 has been studied for its effects on reducing intestinal permeability, a condition in which the tight junctions between intestinal wall cells become compromised, allowing larger molecules to enter the bloodstream. One hypothesis in autoimmune disease research holds that increased intestinal permeability may contribute to the antigenic exposure that triggers or perpetuates autoimmune responses, including autoimmune thyroid disease. BPC-157 also reduces inflammatory cytokines, particularly TNF-alpha, and supports tissue repair through angiogenesis, the growth of new blood vessels into damaged tissue.

The evidence for BPC-157 in Graves' disease is experiential rather than clinical. No human trial has measured TSH receptor antibody levels, free T4, or any Graves'-specific marker in response to BPC-157 administration. Practitioners who include it in autoimmune thyroid protocols do so for its anti-inflammatory and gut-repair properties rather than for any direct action on thyroid antibodies. Most adjacent user experience comes from the Hashimoto's community, where gut healing benefits have been reported. BPC-157 is not FDA-approved and is sold as a research chemical, a category that carries real quality concerns: products in unregulated channels vary in purity, labeling accuracy, and contamination risk. Anyone considering BPC-157 alongside an active autoimmune condition should weigh that quality uncertainty alongside the absence of controlled evidence for this specific use.

6. Thyreogen: A Thyroid Bioregulator That Requires Honest Framing for Graves'

Thyreogen is a dipeptide composed of lysine and glutamic acid, developed from thyroid tissue and belonging to the peptide bioregulator class. Bioregulators of this type are described as tissue-specific: the claim is that they support the cellular function and homeostasis of the tissue from which they derive. In Thyreogen's case, that tissue is the thyroid gland.

The proposed mechanism involves binding to thyroid cell DNA and modulating gene expression in ways thought to support thyroid tissue health and regulation. Within the peptide bioregulator framework, Thyreogen is positioned as a thyroid-support compound, and it circulates in bioregulator protocols addressing thyroid function broadly.

Here is the honest framing for Graves' disease specifically: the fundamental problem in Graves' is not an underperforming thyroid. It is an over-stimulated one. The thyroid is already producing too much hormone because of unregulated antibody-driven activation. A compound whose stated purpose is to support thyroid tissue function and promote thyroid cellular activity presents a conceptual mismatch with the hyperthyroid phase of the disease. The theoretical concern is that stimulating or supporting a thyroid already being driven into overdrive by autoimmune antibodies could worsen hyperthyroid symptoms. No published clinical data resolves this question for Graves' patients in either direction.

No peer-reviewed clinical trial data for Thyreogen in Graves' disease has been identified. The compound is discussed in the peptide bioregulator space primarily as a thyroid-health supplement rather than as a Graves'-specific therapy, and its use among people with Graves' appears to be occasional and anecdotal. It earns a place on this list because the thyroid bioregulator category is a recognized part of the peptide landscape that people with thyroid conditions encounter and ask about. The straightforward answer is that the evidence for any benefit in Graves' disease is absent, and the theoretical concern about worsening hyperthyroid activity during the active phase warrants a direct conversation with the treating physician before any use is considered. Thyreogen is not FDA-approved and is available as a supplement or research compound in some markets.

How These Peptides Compare

Frequently Asked Questions

Has any peptide been tested in humans specifically for Graves' disease?

One compound has: ATX-GD-59 completed a Phase 1 open-label trial in twelve Graves' patients and published preliminary results showing reductions in thyroid hormone levels and receptor antibody concentrations in roughly half the participants. That is the entirety of human trial data in this space as of 2026. No peptide has completed a randomized controlled trial for Graves' disease, and no peptide is approved for this use in any major regulatory market.

Can these peptides replace antithyroid medications for Graves' disease?

No peptide currently has the evidence to support replacing conventional Graves' treatments such as antithyroid medications, radioactive iodine, or surgery. The off-label and experimental compounds discussed here are used, where they are used at all, as adjuncts alongside standard medical management, not as substitutes for it. Anyone managing active Graves' disease should do so under the supervision of a qualified endocrinologist.

Why do some peptides get discussed for Graves' when their evidence comes from Hashimoto's research?

Graves' disease and Hashimoto's thyroiditis are both autoimmune thyroid conditions that share some immune pathway features, including abnormal T-cell regulation and elevated thyroid antibodies, even though their clinical effects are opposite. Some practitioners and users draw on adjacent evidence from Hashimoto's research when considering compounds like Thymosin Alpha-1 or BPC-157 for Graves'. That extrapolation has theoretical logic but is not validated by direct Graves'-specific evidence, and the two conditions have distinct enough mechanisms that findings from one do not reliably transfer to the other.

Is Thyreogen safe to use during the active hyperthyroid phase of Graves' disease?

This is an open question without a definitive clinical answer. Thyreogen is a thyroid tissue bioregulator positioned to support thyroid cellular activity, and in active Graves' disease the thyroid is already being over-stimulated by autoimmune antibodies. Using a thyroid-supporting compound during the hyperthyroid phase carries a plausible risk of worsening that over-stimulation. No published clinical data establishes either safety or harm for Thyreogen in Graves' patients. Anyone considering it should raise this question directly with their treating physician before use.

Do any of the preclinical peptides show effects on Graves' eye disease?

Both P19 and Cyclic Peptide 836, the two leading preclinical peptides, showed reductions in orbital tissue changes in mouse models, including reduced mucin and collagen deposition in retro-orbital tissue and reduced retro-orbital fibrosis. These findings are from animal research only and have not been replicated in humans. The only approved treatment specifically for Graves' orbitopathy is teprotumumab, a monoclonal antibody therapy. No peptide is approved or established for thyroid eye disease management as of 2026.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for Graves' disease in one place.